Fluoroquinolone- and ceftriaxone-based therapy of community-acquired pneumonia in hospitalized patients: the risk of subsequent isolation of multidrug-resistant organisms.

Autor: Goldstein RC; Division of Infectious Diseases, Department of Medicine, Beth Israel Medical Center, New York, NY., Husk G; Department of Emergency Medicine, Beth Israel Medical Center, New York, NY., Jodlowski T; Division of Infectious Diseases, Department of Medicine, Beth Israel Medical Center, New York, NY., Mildvan D; Division of Infectious Diseases, Department of Medicine, Beth Israel Medical Center, New York, NY., Perlman DC; Division of Infectious Diseases, Department of Medicine, Beth Israel Medical Center, New York, NY., Ruhe JJ; Division of Infectious Diseases, Department of Medicine, Beth Israel Medical Center, New York, NY. Electronic address: jorgruhe25@yahoo.com.
Jazyk: angličtina
Zdroj: American journal of infection control [Am J Infect Control] 2014 May; Vol. 42 (5), pp. 539-41.
DOI: 10.1016/j.ajic.2014.01.005
Abstrakt: A retrospective cohort study was performed on 175 adult patients treated for community-acquired pneumonia with moxifloxacin or ceftriaxone/azithromycin in a nonintensive care unit. Both cohorts were very similar with regard to a wide range of characteristics including age, severity of disease, comorbidities, length of stay, and mortality. Multidrug-resistant organisms were subsequently isolated from 6 (15%) moxifloxacin-treated patients and 5 (4%) ceftriaxone/azithromycin-treated patients within 90 days after beginning of therapy (P = .026 on logistic regression analysis).
(Copyright © 2014 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Mosby, Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: